With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Robert L. Ferris, MD, ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by ...
Dr. Costa emphasizes that absence of prior BCMA-directed therapy and treatment history represent fundamental elements guiding ...
A new cross-sectional analysis reveals that young adult cancer survivors in the United States face a significantly higher ...
The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma ...
The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
Matched sibling donors (MSD) and matched unrelated donors (MUD) continue to yield the best 2-year survival outcomes following allogeneic hematopoietic cell transplantation (HCT), while mismatched ...
Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: ...
Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases. During a visit to Columbia University’s Herbert Irving Comprehensive Cancer Center, ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results